---
schema_version: "secwatch.filing_event.v1"
accession: "0001297184-25-000058"
form_type: "8-K"
ticker: "AMPH"
cik: "0001297184"
company_name: "Amphastar Pharmaceuticals, Inc."
filed_at: "2025-10-24T23:59:59+00:00"
generated_at: "2026-05-17T02:18:52.963836+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Amphastar enters exclusive BAQSIMI distribution deal for Greater China with related party

## Summary
- Exclusive distributor Chengong will market BAQSIMI in Mainland China, Taiwan, Hong Kong, Macau.
- Chengong must obtain regulatory approvals and conduct post-marketing clinical trials.
- 10-year term; minimum purchase amounts per contract year; profit sharing above floor price.
- Related party: CEO Jack Zhang and Chairman Mary Luo family own majority of Chengong's parent Hanxin.
- Audit Committee approved the deal; total revenue over 10 years not yet determinable.

## SEC filing metadata
- accession: 0001297184-25-000058
- form_type: 8-K
- ticker: AMPH
- cik: 0001297184
- company_name: Amphastar Pharmaceuticals, Inc.
- filed_at: 2025-10-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1297184/000129718425000058/0001297184-25-000058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1297184/000129718425000058/amph-20251021x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001297184-25-000058
- JSON: https://secwatch.observer/filing/0001297184-25-000058.json
- Plain text: https://secwatch.observer/filing/0001297184-25-000058.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.